Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Eryaspase + Fluorouracil + Irinotecan + Leucovorin|
|Synonyms||Eryaspase + FOLFIRI|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Eryaspase||Eryaspase consists of asparaginase encapsulated within erthyrocytes, which has potential antitumor activity (PMID: 31760314).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 14||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Leucovorin||Wellcovorin||Calcium folinate|Calcium citrovorum factor|folinic acid||Chemotherapy - Antimetabolite 14||Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03665441||Phase III||Eryaspase + Gemcitabine + Nab-paclitaxel Eryaspase + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel||Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (Trybeca-1)||Active, not recruiting||USA | FRA||1|